We are advancing a pipeline focused on serious CNS diseases with significant unmet clinical need.
*Status of sGC programs as of January 1, 2021. Represents ongoing phase of development; does not correspond to the initiation or completion of a particular phase.
CY6463 is the revised compound name for IW-6463. IW-6463 will be referenced in various existing articles, trial descriptions, etc.